Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension

Abstract Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase-5 inhibitor, has shown promising results as a novel oral monotherapy in the treatment of pulmonary arterial hypertension (PAH). We conducted a cross-sectional survey of 19 consecutive PAH p...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2007-07, Vol.119 (3), p.400-402
Main Authors: Wong, Raymond Ching-Chiew, Koh, Geok Mui, Choong, Poh Hoon, Yip, Wei Luen James
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular
Cross-Sectional Studies
Exercise Tolerance
Facial bones, jaws, teeth, parodontium: diseases, semeiology
Functional class
Health Status
Health-related quality of life
Humans
Hypertension, Pulmonary - drug therapy
Medical sciences
Middle Aged
Non tumoral diseases
Oral sildenafil
Otorhinolaryngology. Stomatology
Phosphodiesterase Inhibitors - therapeutic use
Piperazines - therapeutic use
Pneumology
Pulmonary arterial hypertension
Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
Purines - therapeutic use
Quality of Life
Sildenafil Citrate
Sulfones - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase-5 inhibitor, has shown promising results as a novel oral monotherapy in the treatment of pulmonary arterial hypertension (PAH). We conducted a cross-sectional survey of 19 consecutive PAH patients, aged 16–75 years, with WHO functional class II or worse over 3 months of oral sildenafil. Improvement in exercise capacity was achieved in 15/19 (79%) patients. 6-minute walk test distance increased from 299 ± 118 m to 360 ± 127 m, p = 0.016, and WHO functional class decreased significantly. Both PASP and CI showed a non-significant trend toward improvement. Patients also reported significant improvement in physical ( p = 0.002) and social ( p < 0.001) functioning, and general health ( p = 0.01) of Rand SF-36 questionnaire. There was improvement in domains of role limitation due to physical health ( p = 0.16), emotion ( p = 0.14), and energy level ( p = 0.4). Our study suggests that oral sildenafil monotherapy is effective in improving exercise capacity and health-related quality of life amongst PAH patients.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2006.07.170